(2-chloro-pyridin-3-yl)-(3-methoxy-phenyl)-methanol | 80100-20-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (2-chloro-pyridin-3-yl)-(3-methoxy-phenyl)-methanol
• 英文别名: 3-methoxyphenyl-2-chloropyrid-3-ylmethanol；2-chloro-α-(3-methoxyphenyl)-3-pyridinemethanol；2-Chloro-alpha-(3-methoxyphenyl)-3-pyridinemethanol；(2-chloropyridin-3-yl)-(3-methoxyphenyl)methanol
• CAS: 80100-20-5
• 化学式: C₁₃H₁₂ClNO₂
• 分子量: 249.697
• InChiKey: MCPVWWWJDZZVBK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  42.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2-chloro-pyridin-3-yl)-(3-methoxy-phenyl)-methanol 在 对甲苯磺酸 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 10.0h， 生成 2-chloro-3-[(3-methoxyphenyl)({1-[(piperidin-1-yl)carbonyl]azetidin-3-yl}oxy)methyl]pyridine
  参考文献：
  名称：

  Fatty acid amide hydrolase inhibitors. 3: Tetra-substituted azetidine ureas with in vivo activity

  摘要：

  We describe here our attempts to optimise the human fatty acid amide hydrolase (FAAH) inhibition and physicochemical properties of our previously reported tetrasubstituted azetidine urea FAAH inhibitor, VER-156084. We describe the SAR of a series of analogues and conclude with the demonstration of in vivo dose-dependant FAAH inhibition in an anandamide-loading study in rats. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.12.032
• 作为产物：
  描述：

  2-氯吡啶 、 3-甲氧基苯甲醛 在 ammonium chloride 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙酸乙酯 为溶剂， 以51%的产率得到(2-chloro-pyridin-3-yl)-(3-methoxy-phenyl)-methanol
  参考文献：
  名称：

  Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as D4 antagonists

  摘要：

  公开号：

  EP1216244B1

文献信息

• 2-halo-pyridines
  申请人：Lacer, S.A.

  公开号：US04614833A1

  公开（公告）日：1986-09-30

  2-Halo-pyridines of the general formula I ##STR1## wherein X is Cl or Br; A is .dbd.0 or ##STR2## Ar is phenyl or substituted phenyl of the general formula ##STR3## in which n is 0, 1, 2 or 3; R is alkyl C.sub.1-4, alkoxy C.sub.1-4, phenoxy, alkylthio C.sub.1-4, halogen especially F and Cl, OH or C.sub.6 H.sub.5 ; and their salts, addition compounds and precursors (prodrugs). Furthermore the invention is directed to the production of these compounds and pharmaceuticals containing them.

  2-卤代吡啶的一般化学式为I，其中X为Cl或Br；A为.dbd.0或Ar；Ar为苯基或一般化学式为##STR3##的取代苯基，其中n为0、1、2或3；R为烷基C.sub.1-4、烷氧基C.sub.1-4、苯氧基、烷硫基C.sub.1-4、卤素特别是F和Cl、羟基或C.sub.6 H.sub.5；以及它们的盐、加合物和前体药物（前药）。此外，本发明涉及这些化合物的制备以及含有它们的药物。
• Benzisoxazolyl-,pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists
  申请人：Shutske M. Gregory

  公开号：US20050107377A1

  公开（公告）日：2005-05-19

  The compounds are of the class of benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives, useful as D 4 antagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of D 4 receptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, Parkinsonism, Tardive Diskinesia, Gilles de la Tourette Syndrome, Conduct Disorder, and Oppositional Defiant Disorder. A further aspect of the invention is to provide a pharmaceutical composition, intermediates, and a method of making said class of compounds.

  这些化合物属于苯并异噁唑基、吡啶异噁唑基和苯并噻吩基苯氧基衍生物类，可用作D4拮抗剂。这些化合物可用于治疗由D4受体抑制引起的医疗状况，例如注意力缺陷多动障碍、强迫症、精神病、物质滥用、物质依赖、帕金森病、帕金森综合症、迟发性运动障碍、图雷特综合症、行为障碍和反抗性障碍等。本发明的另一个方面是提供一种制药组合物、中间体和制备该类化合物的方法。
• 2-halo-aryl-pyridinemethanols with analgesic or antiinflammatory activity
  申请人：Lacer, S.A.

  公开号：US04736037A1

  公开（公告）日：1988-04-05

  2-Halo-pyridine of the formula: ##STR1## wherein X is Cl or Br; Ar is phenyl or substituted phenyl of the formula ##STR2## in which n is 0, 1, 2 or 3; R is C.sub.1-4 alkyl, C.sub.1-4 alkoxy, phenoxy, C.sub.1-4 alkylthio, halogen, OH or C.sub.6 H.sub.5 ; or a pharmaceutically acceptable salt thereof.

  公式为：##STR1## 其中X为Cl或Br；Ar为苯或公式##STR2##中的取代苯，其中n为0、1、2或3；R为C.sub.1-4烷基、C.sub.1-4烷氧基、苯氧基、C.sub.1-4烷硫基、卤素、OH或C.sub.6 H.sub.5；或其药学上可接受的盐。
• Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists
  申请人：Aventis Pharmaceuticals Inc.

  公开号：US07253165B2

  公开（公告）日：2007-08-07

  The compounds are of the class of benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives, useful as D4 antagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of D4 receptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, Parkinsonism, Tardive Diskinesia, Gilles de la Tourette Syndrome, Conduct Disorder, and Oppositional Defiant Disorder. A further aspect of the invention is to provide a pharmaceutical composition, intermediates, and a method of making said class of compounds.

  这些化合物属于苯并异噁唑基、吡啶并异噁唑基和苯并噻吩基苯氧衍生物类，可作为D4拮抗剂使用。这些化合物可用于治疗由D4受体抑制引起的医疗状况。这些状况包括，例如，注意力缺陷多动障碍、强迫症、精神病、物质滥用、物质依赖、帕金森病、帕金森综合症、迟发性运动障碍、吉尔斯-德-拉-图雷综合症、行为障碍和反抗性障碍。本发明的另一个方面是提供一种制药组合物、中间体和制备该类化合物的方法。
• New 2-halo-pyridines, their production and pharmaceutical compositions
  申请人：LACER, S.A.

  公开号：EP0032516B1

  公开（公告）日：1984-05-02